Abstract OBJECTIVE: To study the regulatory role of bacterial lipopolysaccharide (LPS ) in the development of bronchial asthma by examining the effects of LPS on serum IL-4, serum IL-8 and pulmonary vascular endothelial growth factor (VEGF) expression in mice with asthma. METHODS: Twenty-seven BALB/c mice were randomly assigned into control, asthma and LPS-treated asthma groups (n=9 each). Serum IL-4 and IL-8 concentrations were measured using ELISA. VEGF expression in lung tissues was examined using the immunohistochemical method. RESULTS: Serum IL-4 and IL-8 concentrations in the asthma group were significantly higher than in the control group (P<0.05). LPS treatment significantly decreased serum IL-4 and IL-8 concentrations compared with the asthma group (P<0.05), although levels were significantly higher than in the control group (P<0.05). Airway VEGF expression in the asthma group was significantly higher than in the control group (P<0.05). LPS treatment significantly decreased airway VEGF expression compared with the asthma group (P<0.05), although concentrations remained higher than in the control group (P<0.05). CONCLUSIONS: LPS can decrease serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma, and thus can possibly reduce both airway inflammation and airway vascular remodeling.
LUAN Bin,FENG Mei-Jing,QIAO Jun-Ying. Effects of bacterial lipopolysaccharide on serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma[J]. 中国当代儿科杂志, 2012, 14(4): 297-300.
LUAN Bin,FENG Mei-Jing,QIAO Jun-Ying. Effects of bacterial lipopolysaccharide on serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma[J]. CJCP, 2012, 14(4): 297-300.
［1］Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children［J］. N Engl J Med, 2002, 347(12): 869-877.
［6］Steinke JW, Borish. TH2 cytokine and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists［J］. Respir Res, 2001, 2(20): 66-70.
［7］Randolph DA, Stephens R, Carruthers CJ, Chaplin DD. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation［J］. J Clin Invest, 1999, 104(8):1021-1029.
［8］Ryan JJ, McReynolds LJ, Keegan A, Wang LH, Garfein E, Rothman P, et al. Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor［J］. Immunity, 1996, 4(2):123-132.
［9］Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation［J］. J Allergy Clin Immunol, 1995, 95（4）: 843-852.
［10］Takeda K, Kaisho T, Akira S. Toll-like receptors［J］. Annu Rev Immunol, 2003, 21: 335-376.
［13］Walters EH, Reid D, Soltani A, Ward C. Angiogenesis: apotentially critical part of remodelling in chronic airway diseases?［J］. Pharmacol Ther, 2008, 118(1): 128-137.
［14］Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors［J］. Nat Med, 2003, 9(6): 669-676.
［15］Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung［J］. Am J Physiol Lung Cell Mol Physiol, 2006, 290(2): L209-L221.
